Want to see FR:AB full AI Analyst Report?
AB Stock Chart & Stats
€1.48
€0.14(8.88%)
At close: 4:00 PM EST
€1.48
€0.14(8.88%)
Day’s Range― - ―
52-Week Range€0.72 - €1.73
Previous CloseN/A
Volume459.42K
Average Volume (3M)323.75K
Market Cap
€55.67M
Enterprise Value€55.46M
Total Cash (Recent Filing)€10.18M
Total Debt (Recent Filing)€4.24M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Sep 25, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding73,251,990
10 Day Avg. Volume89,975
30 Day Avg. Volume323,750
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€1.20M
Bulls Say, Bears Say
Bulls Say
Leverage ReductionA meaningful reduction in debt by 2025 materially lowers interest and refinancing pressure and improves near-term solvency risk. This gives management more optionality to fund clinical programs or seek partnerships without immediate debt-servicing strain.
Improving Revenue TrendConsistent top-line growth, with a stronger 2025, indicates improving commercial traction or milestone-related inflows. Sustained revenue growth helps lengthen runway and supports incremental investment in trials or commercialization if trends continue.
Diversified Clinical PipelineA single molecule pursued across multiple indications reduces binary program risk and increases strategic optionality. Multi-indication development can attract partnerships, spread R&D investment across assets, and create multiple commercialization pathways.
Bears Say
Negative Shareholders' EquityPersistently negative equity is a structural solvency red flag that constrains financing alternatives and creditor confidence. It reduces flexibility to absorb further losses and can force dilutive or costly funding solutions if losses persist.
Renewed Cash BurnReturn to significant negative operating and free cash flow increases near-term liquidity and funding risk. Ongoing cash burn necessitates external capital or partner funding, raising dilution risk and potentially delaying or scaling back clinical plans.
Persistent UnprofitabilityChronic, material losses undermine internal capacity to fund R&D and commercialization, making long-term sustainability dependent on financing or deals. Continued unprofitability increases execution and survival risk absent sustained revenue gains.
AB Science SA News
AB FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was €0.72 and its highest was €1.73 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is €55.67M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 78 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -€0.07 earnings per share for the quarter, the consensus estimate of -€0.07 by €0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.07.
How many shares outstanding does AB Science SA have?
AB Science SA has 73,251,990 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -€0.07 in its last earnings report, expectations of -€0.07. Following the earnings report the stock price went down -3.32%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in FR:AB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.